News & Updates

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Clinicians must be aware of the likelihood of infection with herpes simplex virus (HSV) in the presence of fissures, haemorrhagic crusts, linear erosions, erosions with angulated margins, and increased erythrocyte sedimentation rate among patients with pemphigus vulgaris, suggests a study.

The incidence of psoriasis may be decreased by maintaining a normal weight and by putting a stop to the use of tobacco and cigarettes, a recent study has shown. In addition, addressing the inequality in education may help lower the cases of this condition.

Outpatient oritavancin therapy appears to be more effective than inpatient standard-of-care (SoC) in reducing 30-day hospital readmissions or admissions among individuals with acute uncomplicated cellulitis, a recent study has shown.

Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.

Treatment with oral ritlecitinib improves outcomes in patients with active nonsegmental vitiligo, without any serious adverse events over 48 weeks, results of a study have shown.

An online health model appears to be as effective as in-person care for decreasing functional impairment and depressive symptoms in patients with psoriasis, according to a study.

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.